In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex®, would ...
The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations capturing 67.5% market share as the industry ...
VV169 saw complete clearance of disseminated myeloma tumors within 28 daysAnother dataset highlights Vyriad’s work in improved vector retargeting strategies in a comparative study of three methods for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback